Hjem › Urotelial (overgangscelle) carcinom › Massachusetts
Urotelial (overgangscelle) carcinom kliniske forsøg i Massachusetts
15 studier for Urotelial (overgangscelle) carcinom søger deltagere på steder i Massachusetts.
Byer i Massachusetts
Officiel studietekst (engelsk)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #7, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- UMass Memorial Medical Center - University Campus, Worcester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06524544A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07090499Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT05874921Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06047379A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Massachusetts General Hospital, Boston
- University of Massachusetts Medical School, Worcester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07218380Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06293898Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06966024An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Boston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- UMass Memorial Medical Center, Worcester
- University of Massachusetts Chan Medical School, Worcester
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT04879329This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT06451497Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
- Dana-Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alder 65 og opefter · Alle køn · Opdateret 17. feb. 2026 · NCT06138561Sacituzumab Govitecan Plus EV in Metastatic UC
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. nov. 2025 · NCT04724018SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.